Publication | Closed Access

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action

UrologyMedicineHormonal ReceptorPharmacologyClinical PharmacologyPharmacotherapy5-Alpha-reductase InhibitorAnti-cancer AgentProstatic DiseaseOncologyEndocrine-related Cancer